| Style | Citing Format |
|---|---|
| MLA | Mirzaeiyan M, et al.. "Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer." Journal of Biomedical Physics and Engineering, vol. 16, no. 1, 2026, pp. 1-10. |
| APA | Mirzaeiyan M, Hemati S, Akhavan A, Etehadtavakol M, Sharifonnasabi Z, Amouheidari A, Adibi A, Khanahmad H, Shokrani P (2026). Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer. Journal of Biomedical Physics and Engineering, 16(1), 1-10. |
| Chicago | Mirzaeiyan M, Hemati S, Akhavan A, Etehadtavakol M, Sharifonnasabi Z, Amouheidari A, Adibi A, Khanahmad H, Shokrani P. "Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer." Journal of Biomedical Physics and Engineering 16, no. 1 (2026): 1-10. |
| Harvard | Mirzaeiyan M et al. (2026) 'Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer', Journal of Biomedical Physics and Engineering, 16(1), pp. 1-10. |
| Vancouver | Mirzaeiyan M, Hemati S, Akhavan A, Etehadtavakol M, Sharifonnasabi Z, Amouheidari A, et al.. Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer. Journal of Biomedical Physics and Engineering. 2026;16(1):1-10. |
| BibTex | @article{ author = {Mirzaeiyan M and Hemati S and Akhavan A and Etehadtavakol M and Sharifonnasabi Z and Amouheidari A and Adibi A and Khanahmad H and Shokrani P}, title = {Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer}, journal = {Journal of Biomedical Physics and Engineering}, volume = {16}, number = {1}, pages = {1-10}, year = {2026} } |
| RIS | TY - JOUR AU - Mirzaeiyan M AU - Hemati S AU - Akhavan A AU - Etehadtavakol M AU - Sharifonnasabi Z AU - Amouheidari A AU - Adibi A AU - Khanahmad H AU - Shokrani P TI - Evaluation of Variability of Dosiomics Features With Varying Prescribed Dose in Prostate Cancer JO - Journal of Biomedical Physics and Engineering VL - 16 IS - 1 SP - 1 EP - 10 PY - 2026 ER - |